






INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁴ : C07J 41/00, A61K 31/565		A1	(11) International Publication Number: WO 88/ 08002 (43) International Publication Date: 20 October 1988 (20.10.88)
(21) International Application Number: PCT/US88/00978 (22) International Filing Date: 1 April 1988 (01.04.88) (31) Priority Application Numbers: 039,042 062,276 (32) Priority Dates: 16 April 1987 (16.04.87) 15 June 1987 (15.06.87) (33) Priority Country: US (60) Parent Applications or Grants (63) Related by Continuation US 039,042 (CIP) Filed on 16 April 1987 (16.04.87) US 062,276 (CIP) Filed on 15 June 1987 (15.06.87) (71) Applicant (for all designated States except US): THE UPJOHN COMPANY [US/US]; 301 Henrietta Street, Kalamazoo, MI 49001 (US).		(72) Inventors; and (75) Inventors/Applicants (for US only) : BUNDY, Gordon, L. [US/US]; 7622 Ravenswood Drive, Kalamazoo, MI 49002 (US). YOUNGDALE, Gilbert, A. [US/US]; 1702 Greenbriar Drive, Portage, MI 49002 (US). (74) Agent: BUSSE, Paul, W.; Patent Law Department, The Upjohn Company, Kalamazoo, MI 49001 (US). (81) Designated States: AT (European patent), AU, BE (Eu- ropean patent), CH (European patent), DE (Euro- pean patent), DK, FI, FR (European patent), GB (European patent), IT (European patent), JP, KR, LU (European patent), NL (European patent), NO, SE (European patent), US, US. Published With international search report.	

(54) Title: CYCLIC HYDROCARBONS WITH AN AMINOALKYL SIDECHAIN



(57) Abstract

This invention provides novel cyclic hydrocarbons of formula (I), wherein R is selected from the group consisting of $\text{CH}_2=\text{CH}-\text{CH}_2$, $\text{HO}-\text{CH}_2\text{CH}_2\text{CH}_2$, and CH_3 ; wherein R_1 is selected from the group consisting of m-trifluoromethyl-phenylmethyl, 2-thienylmethyl, and p-aminosulfonylphenylethyl; wherein R_2 and R_3 are methyl or hydrogen; wherein R_4 is hydrogen or -OH; a compound of formula (II), wherein R is $(\text{CH}_3)_2\text{NCH}_2\text{CH}_2\text{CH}_2$ or $\text{NH}_2\text{CH}_2\text{CH}_2\text{CH}_2$; and pharmacologically acceptable salts thereof; or a compound of formula (III), wherein the dashed line indicates that the 2-3 bond is saturated or unsaturated and, wherein R is hydrogen or methyl. These compounds are useful for inhibiting adverse physiological symptoms associated with phospholipase A_2 and for treating hyperglycemia associated diseases such as diabetes and obesity.